MONTREAL, June 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will hold a video conference call on Tuesday, June 13, 2023, to update investors and analysts on the Phase 1 trial of its lead peptide-drug conjugate (PDC) candidate, sudocetaxel zendusortide (formerly TH1902), for the treatment of solid tumors.
During the call, Theratechnologies will provide insights on preliminary Phase 1 safety and efficacy data that were presented at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), as well as the U.S. Food and Drug Administration’s (FDA) recent agreement to the Company’s amended Phase 1 trial protocol. Both events are significant milestones in the development of sudocetaxel zendusortide, a PDC that targets the sortilin (SORT1) receptor, and a product of Theratechnologies’ SORT1+ Technology™ platform.
Paul Lévesque, President and Chief Executive Officer of Theratechnologies, will host the call, which will feature presentations from the Company’s Senior Vice President and Chief Medical Officer, Christian Marsolais, Ph.D., as well as from investigators from the Phase 1 trial. Presenters will be available to answer questions following prepared remarks.
Registration information:
| Title: | Oncology Investigator Call for Investors & Analysts: Phase 1 Trial Update |
| Date: | June 13, 2023 |
| Time: | 10:00 AM EDT |
| Webcast link: | https://edge.media-server.com/mmc/p/u5gusxvs |
| Dial in: | 1-888-317-6003 (toll free) or 1-412-317-6061 (International) (Participant entry #: 2792560) |
An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’.
About SORT1+ Technology™ and Sudocetaxel Zendusortide (TH1902)
Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and trafficking. Expression of SORT1 is associated with aggressive disease, poor prognosis, and decreased survival. It is estimated that SORT1 is expressed in 40% to 90% of endometrial, ovarian, colorectal, triple-negative breast (TNBC), and pancreatic cancers, making this receptor an attractive target for anticancer drug development.
Sudocetaxel zendusortide is a first-of-its-kind SORT1-targeting PDC, and the first compound to emerge from the SORT1+ Technology™ platform. A new chemical entity, sudocetaxel zendusortide employs a cleavable linker to conjugate (attach) a proprietary peptide to docetaxel, a well-established cytotoxic chemotherapeutic agent used to treat many cancers. The FDA granted Fast Track designation to sudocetaxel zendusortide as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy. Sudocetaxel zendusortide is currently being evaluated in a Phase 1 clinical trial.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com , on SEDAR at www.sedar.com and on EDGAR at www.sec.gov .
Forward-Looking Information
This press release contains forward-looking statements and forward-looking information (collectively, “Forward-Looking Statements”), within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as “may”, "outlook", "believe", "plan", "envisage", "anticipate", "expect", and "estimate", or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding , the development of sudocetaxel zendusortide and other PDCs stemming from the SORT1+ Technology™ platform, the resumption of the Phase 1 clinical trial using sudocetaxel zendusortide and the recruitment of patients, the optimization of the dosing of sudocetaxel zendusortide, and potential efficacy and safety results to be derived from the use of sudocetaxel zendusortide for the treatment of cancer. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements. Certain assumptions made in preparing the Forward-Looking Statements include that the Company will be able to recruit patients meeting the selection criteria in a number sufficient to conduct the Phase 1 clinical trial, the proposed dosing regimen will result in strong efficacy data with no safety concerns, research and development activities will generate new PDCs and no unplanned event will cause the Phase 1 clinical trial to be halted or cancelled. Forward-Looking Statements are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies’ control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to, the impossibility of demonstrating the safe and effective use of sudocetaxel zendusortide in our clinical trials, the incapacity of the Company to recruit a sufficient number of patients to resume the Phase 1 clinical trial, and the incapacity of the Company to obtain positive results from the continuous development of its SORT1+ TechnologyTM platform. We refer current and potential investors to the “Risk Factors” section of our Annual Information Form dated February 27, 2023, available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov as an exhibit to our report on Form 40-F dated February 28, 2023, under Theratechnologies’ public filings, for additional risks related to the Company. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on Forward-Looking Statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
ir@theratech.com
1-438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
1-514-336-7800
